A Phase 2 interventional study of RSVPreF3 OA Investigational Vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 46 sites in 8 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 15th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 2, and was the 8th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 386 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 27th largest by enrollment, is one of 4 that started in 2023, is one of 9 in phase 2, and was the 30th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Specific inclusion criteria for renal/lung transplant patients:
Specific inclusion criteria for renal transplant (RTx) patients:
Specific inclusion criteria for lung transplant (LTx) patients:
Specific inclusion criteria for healthy participants:
Exclusion Criteria:
Medical conditions:
Prior/Concomitant therapy:
Prior/Concurrent clinical study experience:
Other exclusion criteria:
Specific exclusion criteria for renal/lung transplant patients:
Specific exclusion criteria for RTx patients:
Specific exclusion criteria for LTx patients:
Specific exclusion criteria for healthy participants:
Chronic administration of immune-modifying drugs (>14 days in total) and/or administration of long-acting immune-modifying treatments or planned administration at any time up to the end of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunocompromised (IC) participants (recipients of lung or renal transplant) received 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
Biological: RSVPreF3 OA Investigational Vaccine
IC participants (recipients of lung or renal transplant) received 2 doses of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1) and Visit 3 (Visit 1 + 30-60 days).
Biological: RSVPreF3 OA Investigational Vaccine
Healthy adult (HA) participants received 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
Biological: RSVPreF3 OA Investigational Vaccine
0.5 mililiter dose was administered intramuscularly as 1 dose to RSV\_IC\_1 and RSV\_HA groups, and 2 doses to RSV\_IC\_2 group.
RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group
MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-A post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).
Time frame: At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)
RSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group
MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-B post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).
Time frame: At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)
RSV-A And RSV-B Serum Neutralizing Titers Expressed As Geometric Mean Titers (GMT) for RSV_IC_1, RSV_IC_2 and RSV_HA Groups
Neutralizing titers were calculated as GMT and expressed in titers (Estimated Dilution 60 \[ED60\]).
Time frame: At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 in a subset of participants (Visit 1+ 7-14 days), Visit 3 (Visit 1+ 30-60 days), Visit 4 (Visit 3+ 30-42 days), Visit 5 (last dose+ 180-210 days) and Visit 6 (last dose+ 350-380 days)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups
Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups
Group GMT of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups
Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups
Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups
Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups
Group GMT ratio of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups
Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups
Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
RSV-A And RSV-B Serum Neutralizing Titers Expressed As MGI
MGI was assessed at Visit 2 (in a subset of participants) over Visit 1 and Visit 3 over Visit 1 in RSV\_HA and pooled RSV\_IC (combined RSV\_IC\_1 and RSV\_IC\_2 groups), and at Visit 4, Visit 5 and Visit 6 over Visit 1 in RSV\_IC\_1, RSV\_IC\_2, RSV\_HA groups.
Time frame: At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days), each compared to Visit 1 (Day 1)
Cell Mediated Immunity (CMI) Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific Cluster Of Differentiation (CD) 4+ T Cells
CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific cluster of differentiation CD4+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).
Time frame: At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
CMI Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific CD8+ T Cells
CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).
Time frame: At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Number Of Participants Reporting Any Solicited Administration Site Events
Assessed solicited administration site events included pain, erythema (redness) and swelling, at the injection site. Any = occurrence of the symptom regardless of intensity grade.
Time frame: Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Number Of Participants Reporting Any Solicited Systemic Events
Assessed solicited systemic events included fever (pyrexia), myalgia, arthralgia, headache, and fatigue. Fever is defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.
Time frame: Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Number Of Participants Reporting Any Unsolicited Adverse Events (AEs) At Any Dose Administration
An unsolicited AE is an AE that was not included in the list of solicited events. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.
Time frame: Within 30 days (i.e., the day of vaccination and 29 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Number Of Participants Reporting Any Serious Adverse Events (SAEs), SAEs Related To Study Intervention And Fatal SAEs
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity grade or relation to study intervention. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of intensity grade or relation to study intervention.
Time frame: From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Number Of Participants Reporting Any Potential Immune-Mediated Disease (pIMDs) And pIMDs Related To Study Intervention
pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of intensity grade or relation to study intervention. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.
Time frame: From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Number Of Participants With Any AEs Of Special Interest (AESIs) Specific To Renal And Lung Solid Organ Transplant (SOT) Participants
AESIs include the acute rejection of transplant (specific to renal and lung SOT participants). Analysis was performed only on participants that received transplant in RSV\_IC\_1 and RSV\_IC\_2 groups.
Time frame: From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
| Milestone | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Started | 131 | 130 | 125 |
| Completed | 129 | 125 | 123 |
| Not completed | 2 | 5 | 2 |
| Withdrew: Unsolicited non-sae | 0 | 1 | 0 |
| Withdrew: Saes/pimds/aesis specific to sot | 1 | 3 | 1 |
| Withdrew: Withdrawal by participant: burden of procedure | 0 | 1 | 0 |
| Withdrew: Withdrawal by participant: participant relocated | 1 | 0 | 1 |
MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-A post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).
| Ratio | RSV_IC_2 Group |
|---|---|
| RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group | 1.34 (1.20 to 1.48) |
MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-B post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).
| Ratio | RSV_IC_2 Group |
|---|---|
| RSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group | 1.26 (1.14 to 1.40) |
Neutralizing titers were calculated as GMT and expressed in titers (Estimated Dilution 60 \[ED60\]).
| Titers (ED60) | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| RSV-A , Visit 1 | 807.0 (700.9 to 929.2) | 814.1 (701.3 to 945.1) | 889.0 (781.9 to 1010.6) |
| RSV-A , Visit 2 | 1775.8 (1201.0 to 2625.6) | 2031.1 (1283.6 to 3213.9) | 6716.8 (4907.6 to 9193.0) |
| RSV-A , Visit 3 | 3990.8 (3219.4 to 4947.0) | 4174.0 (3230.7 to 5392.6) | 6881.3 (5976.2 to 7923.6) |
| RSV-A , Visit 4 | 4184.7 (3360.1 to 5211.7) | 5377.9 (4265.4 to 6780.6) | 5707.0 (4853.6 to 6710.3) |
| RSV-A , Visit 5 | 3220.8 (2637.4 to 3933.3) | 3954.5 (3205.4 to 4878.6) | 3958.4 (3372.2 to 4646.6) |
| RSV-A , Visit 6 | 1773.4 (1486.2 to 2116.2) | 2517.4 (2039.3 to 3107.5) | 2243.6 (1925.0 to 2614.9) |
| RSV-B, Visit 1 | 864.2 (727.8 to 1026.2) | 892.9 (754.1 to 1057.3) | 1027.3 (889.6 to 1186.3) |
| RSV-B, Visit 2 | 2325.3 (1592.9 to 3394.5) | 2603.1 (1714.9 to 3951.3) | 8113.6 (5699.9 to 11549.5) |
| RSV-B, Visit 3 | 5002.9 (3901.7 to 6414.8) | 4834.7 (3736.6 to 6255.6) | 9125.2 (7781.9 to 10700.5) |
| RSV-B, Visit 4 | 4461.7 (3519.0 to 5657.0) | 5820.8 (4658.2 to 7273.5) | 6281.6 (5377.6 to 7337.7) |
| RSV-B, Visit 5 | 2926.9 (2364.0 to 3623.8) | 3620.7 (2974.9 to 4406.7) | 3584.5 (3093.6 to 4153.3) |
| RSV-B, Visit 6 | 2206.7 (1811.3 to 2688.5) | 2886.5 (2368.0 to 3518.4) | 2665.1 (2310.9 to 3073.5) |
Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_HA Group | Pooled RSV_IC Group |
|---|---|---|
| Visit 2 | 6689.9 (4639.3 to 9646.7) | 1902.8 (1479.6 to 2446.9) |
| Visit 3 | 6714.9 (5549.8 to 8124.7) | 4111.4 (3594.3 to 4703.1) |
Group GMT of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_IC_1 Group | RSV_IC_2 Group |
|---|---|---|
| Visit 4 | 4041.9 (3254.8 to 5019.3) | 5098.4 (4088.8 to 6357.3) |
| Visit 5 | 3198.7 (2642.2 to 3872.5) | 3726.3 (3035.9 to 4573.8) |
| Visit 6 | 1737.0 (1459.2 to 2067.8) | 2360.0 (1966.4 to 2832.5) |
Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_IC_1 Group | RSV_HA Group |
|---|---|---|
| Visit 4 | 4244.8 (3551.8 to 5073.0) | 5541.6 (4622.0 to 6644.2) |
| Visit 5 | 3359.9 (2856.5 to 3952.1) | 3804.2 (3227.3 to 4484.1) |
| Visit 6 | 1830.8 (1578.6 to 2123.4) | 2192.9 (1889.6 to 2545.0) |
Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|
| Visit 4 | 5505.3 (4627.0 to 6550.3) | 5615.7 (4719.8 to 6681.6) |
| Visit 5 | 4032.4 (3426.2 to 4746.0) | 3895.6 (3336.5 to 4548.5) |
| Visit 6 | 2555.4 (2196.4 to 2973.1) | 2214.8 (1914.0 to 2562.9) |
Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_HA Group | Pooled RSV_IC Group |
|---|---|---|
| Visit 2 | 8238.7 (5972.9 to 11364.1) | 2442.6 (1958.3 to 3046.7) |
| Visit 3 | 8590.8 (7063.8 to 10448.0) | 5087.8 (4432.0 to 5840.5) |
Group GMT ratio of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_IC_1 Group | RSV_IC_2 Group |
|---|---|---|
| Visit 4 | 4333.3 (3510.0 to 5349.8) | 5550.5 (4478.3 to 6879.4) |
| Visit 5 | 2906.8 (2453.2 to 3444.2) | 3346.4 (2788.7 to 4015.7) |
| Visit 6 | 2158.5 (1851.8 to 2516.0) | 2689.2 (2290.5 to 3157.2) |
Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_IC_1 Group | RSV_HA Group |
|---|---|---|
| Visit 4 | 4632.9 (3890.8 to 5516.6) | 5973.5 (5000.9 to 7135.4) |
| Visit 5 | 3128.7 (2686.0 to 3644.2) | 3390.7 (2903.4 to 3960.0) |
| Visit 6 | 2331.2 (2035.7 to 2669.6) | 2552.1 (2227.3 to 2924.4) |
Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titers (ED60) | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|
| Visit 4 | 6090.6 (5184.6 to 7155.0) | 6123.0 (5212.1 to 7193.0) |
| Visit 5 | 3770.5 (3294.6 to 4315.1) | 3509.7 (3087.0 to 3990.1) |
| Visit 6 | 3003.2 (2631.4 to 3427.4) | 2608.9 (2296.8 to 2963.5) |
MGI was assessed at Visit 2 (in a subset of participants) over Visit 1 and Visit 3 over Visit 1 in RSV\_HA and pooled RSV\_IC (combined RSV\_IC\_1 and RSV\_IC\_2 groups), and at Visit 4, Visit 5 and Visit 6 over Visit 1 in RSV\_IC\_1, RSV\_IC\_2, RSV\_HA groups.
| Ratio | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group | Pooled RSV_IC Group |
|---|---|---|---|---|
| RSV-A, Visit 2 | 2.38 (1.61 to 3.53) | 2.36 (1.56 to 3.58) | 8.48 (6.01 to 11.96) | 2.37 (1.80 to 3.14) |
| RSV-A, Visit 3 | 5.55 (4.44 to 6.95) | 5.90 (4.69 to 7.41) | 8.77 (7.56 to 10.17) | 5.72 (4.88 to 6.70) |
| RSV-A, Visit 4 | 6.88 (5.49 to 8.61) | 8.58 (6.92 to 10.62) | 7.78 (6.66 to 9.09) | — |
| RSV-A, Visit 5 | 4.46 (3.65 to 5.44) | 4.77 (3.93 to 5.79) | 4.54 (3.91 to 5.27) | — |
| RSV-A, Visit 6 | 2.70 (2.26 to 3.22) | 3.50 (2.96 to 4.14) | 2.98 (2.56 to 3.47) | — |
| RSV-B, Visit 2 | 2.51 (1.78 to 3.55) | 2.54 (1.75 to 3.67) | 8.59 (6.59 to 11.20) | 2.53 (1.98 to 3.23) |
| RSV-B, Visit 3 | 5.72 (4.53 to 7.21) | 5.34 (4.25 to 6.72) | 8.95 (7.81 to 10.25) | 5.53 (4.71 to 6.51) |
| RSV-B, Visit 4 | 5.22 (4.20 to 6.49) | 6.52 (5.34 to 7.97) | 6.35 (5.50 to 7.33) | — |
| RSV-B, Visit 5 | 3.52 (2.92 to 4.25) | 3.95 (3.38 to 4.61) | 3.59 (3.13 to 4.10) | — |
| RSV-B, Visit 6 | 2.58 (2.20 to 3.04) | 3.17 (2.73 to 3.68) | 2.69 (2.35 to 3.08) | — |
CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific cluster of differentiation CD4+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).
| Specific CD4+ Tcells/million CD4+ Tcells | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Visit 1 | 86.8 ± 1.0 | 110.3 ± 0.9 | 107.8 ± 0.9 |
| Visit 2 | 2932.2 ± 0.6 | 3704.3 ± 0.5 | 2959.8 ± 0.3 |
| Visit 3 | 1049.0 ± 0.8 | 1626.7 ± 0.3 | 1042.4 ± 0.3 |
| Visit 4 | 910.8 ± 0.8 | 2709.0 ± 0.3 | 734.4 ± 0.3 |
| Visit 5 | 845.4 ± 0.5 | 1452.7 ± 0.4 | 503.7 ± 0.6 |
| Visit 6 | 794.4 ± 0.5 | 1131.9 ± 0.5 | 506.4 ± 0.3 |
CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).
| Specific CD8+ Tcells/million CD8+ Tcells | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Visit 1 | 33.9 ± 1.0 | 8.2 ± 1.1 | 27.7 ± 1.0 |
| Visit 2 | 16.0 ± 1.2 | 8.7 ± 1.0 | 13.0 ± 1.2 |
| Visit 3 | 21.7 ± 0.8 | 22.3 ± 1.1 | 21.0 ± 1.1 |
| Visit 4 | 12.0 ± 1.1 | 16.9 ± 0.9 | 13.2 ± 1.1 |
| Visit 5 | 12.6 ± 1.0 | 14.4 ± 1.1 | 8.2 ± 1.1 |
| Visit 6 | 14.2 ± 1.0 | 20.5 ± 1.1 | 10.6 ± 1.1 |
Assessed solicited administration site events included pain, erythema (redness) and swelling, at the injection site. Any = occurrence of the symptom regardless of intensity grade.
| Participants | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Pain, Within 7 days from Dosing at Visit 1 | 95 | 92 | 95 |
| Pain, Within 7 days from Dosing at Visit 3 | — | 82 | — |
| Erythema, Within 7 days from Dosing at Visit 1 | 8 | 14 | 11 |
| Erythema, Within 7 days from Dosing at Visit 3 | — | 10 | — |
| Swelling, Within 7 days from Dosing at Visit 1 | 8 | 11 | 3 |
| Swelling, Within 7 days from Dosing at Visit 3 | — | 6 | — |
Assessed solicited systemic events included fever (pyrexia), myalgia, arthralgia, headache, and fatigue. Fever is defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.
| Participants | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Fever, Within 7 days from Dosing at Visit 1 | 2 | 1 | 1 |
| Fever, Within 7 days from Dosing at Visit 3 | — | 2 | — |
| Myalgia, Within 7 days from Dosing at Visit 1 | 37 | 38 | 49 |
| Myalgia, Within 7 days from Dosing at Visit 3 | — | 38 | — |
| Arthralgia, Within 7 days from Dosing at Visit 1 | 19 | 15 | 15 |
| Arthralgia, Within 7 days from Dosing at Visit 3 | — | 19 | — |
| Headache, Within 7 days from Dosing at Visit 1 | 31 | 33 | 44 |
| Headache, Within 7 days from Dosing at Visit 3 | — | 30 | — |
| Fatigue, Within 7 days from Dosing at Visit 1 | 41 | 45 | 48 |
| Fatigue, Within 7 days from Dosing at Visit 3 | — | 47 | — |
An unsolicited AE is an AE that was not included in the list of solicited events. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.
| Participants | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Within 7 days from Dosing at Visit 1 | 23 | 33 | 27 |
| Within 7 days from Dosing at Visit 3 | — | 39 | — |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity grade or relation to study intervention. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of intensity grade or relation to study intervention.
| Participants | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Any SAEs | 29 | 37 | 4 |
| Related SAEs | 1 | 0 | 0 |
| Fatal SAEs | 3 | 3 | 0 |
pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of intensity grade or relation to study intervention. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.
| Participants | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Any pIMD | 2 | 1 | 1 |
| Related pIMD | 0 | 0 | 0 |
AESIs include the acute rejection of transplant (specific to renal and lung SOT participants). Analysis was performed only on participants that received transplant in RSV\_IC\_1 and RSV\_IC\_2 groups.
| Participants | RSV_IC_1 Group | RSV_IC_2 Group |
|---|---|---|
| Number Of Participants With Any AEs Of Special Interest (AESIs) Specific To Renal And Lung Solid Organ Transplant (SOT) Participants | 0 | 1 |
Collected over Solicited AEs: within 7 days post each dose administration, and unsolicited AEs: within 30 days post each dose administration, where doses were administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1(Day 1) + 30-60 days] for RSV_IC_2 group). SAEs, related SAEs, fatal SAEs, pIMDs, related pIMDs and AESIs specific for renal/lung transplant: Visit 1 (Day 1) to Visit 6 (last dose + 350-380 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSV_IC_1 Group | 3/131 (2.3%) | 29/131 (22.1%) | 106/131 (80.9%) |
| RSV_IC_2 Group | 3/130 (2.3%) | 37/130 (28.5%) | 120/130 (92.3%) |
| RSV_HA Group | 0/125 (0%) | 4/125 (3.2%) | 111/125 (88.8%) |
| Event | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/131 | 5/130 | 0/125 |
| SepsisInfections and infestations | 1/131 | 4/130 | 0/125 |
| COVID-19Infections and infestations | 0/131 | 4/130 | 0/125 |
| Acute kidney injuryRenal and urinary disorders | 0/131 | 3/130 | 0/125 |
| PyrexiaGeneral disorders | 0/131 | 3/130 | 0/125 |
| Urinary tract infectionInfections and infestations | 2/131 | 2/130 | 0/125 |
| UrosepsisInfections and infestations | 1/131 | 2/130 | 0/125 |
| ColitisGastrointestinal disorders | 0/131 | 2/130 | 0/125 |
| Urinary retentionRenal and urinary disorders | 0/131 | 2/130 | 0/125 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/131 | 2/130 | 0/125 |
| Event | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group |
|---|---|---|---|
| Administration site painGeneral disorders | 95/131 | 108/130 | 95/125 |
| FatigueGeneral disorders | 41/131 | 61/130 | 49/125 |
| MyalgiaMusculoskeletal and connective tissue disorders | 38/131 | 56/130 | 49/125 |
| HeadacheNervous system disorders | 32/131 | 46/130 | 44/125 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/131 | 27/130 | 15/125 |
| Administration site erythemaGeneral disorders | 8/131 | 19/130 | 11/125 |
| Administration site swellingGeneral disorders | 8/131 | 13/130 | 3/125 |
| Administration site pruritusGeneral disorders | 0/131 | 5/130 | 1/125 |
| DiarrhoeaGastrointestinal disorders | 1/131 | 5/130 | 0/125 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/131 | 1/130 | 4/125 |
Exposed set included all participants that received at least one study intervention.
| Age, Continuous(YEARS) | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group | Total |
|---|---|---|---|---|
| Mean | 62.1 ± 9.3 | 61.4 ± 8.4 | 63.8 ± 8.2 | 62.4 ± 8.7 |
| Sex: Female, Male(Participants) | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group | Total |
|---|---|---|---|---|
| Female | 54 | 50 | 66 | 170 |
| Male | 77 | 80 | 59 | 216 |
| Race/Ethnicity, Customized(Participants) | RSV_IC_1 Group | RSV_IC_2 Group | RSV_HA Group | Total |
|---|---|---|---|---|
| White | 89 | 79 | 95 | 263 |
| American Indian Or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 29 | 39 | 24 | 92 |
| Black Or African American | 11 | 8 | 4 | 23 |
| Not Reported | 1 | 2 | 0 | 3 |
| Multiple | 1 | 0 | 1 | 2 |
| Unknown | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Jul 2023 to primary completion in Jun 2024, 10 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 10 months is close to that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →